Quick Answer
Xenon Pharmaceuticals Inc. reported Stockholders Equity of $581.76 million for fiscal year 2025.
Xenon Pharmaceuticals Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $581.76M | -22.9% |
| 2024 | $754.90M | -18.6% |
| 2023 | $927.92M | +28.6% |
| 2022 | $721.50M | +31.2% |
| 2021 | $550.03M | +221.0% |
| 2020 | $171.35M | +86.3% |
| 2019 | $91.98M | -11.0% |
| 2018 | $103.30M | +187.5% |
| 2017 | $35.93M | -43.8% |
| 2016 | $63.90M | +4.7% |
| 2015 | $61.03M | -16.1% |
| 2014 | $72.78M | +192.9% |
| 2013 | -$78.37M | +12.8% |
| 2012 | -$89.86M | -4.1% |
| 2011 | -$86.32M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $559.51M | -29.9% | -11.7% |
| June 30, 2025 | $633.98M | -24.9% | -9.9% |
| March 31, 2025 | $703.96M | -20.7% | -6.7% |
| December 31, 2024 | $754.90M | -18.6% | -5.4% |
| September 30, 2024 | $797.81M | +25.3% | -5.5% |
| June 30, 2024 | $844.05M | +30.6% | -4.9% |
| March 31, 2024 | $887.70M | +29.2% | -4.3% |
| December 31, 2023 | $927.92M | +28.6% | +45.8% |
- Xenon Pharmaceuticals Inc. showed a decrease of -22.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Xenon Pharmaceuticals Inc.’s stockholders equity has grown by 774.0% (from -$86.32 million to $581.76 million).
- The most recent figure is from Xenon Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: